Visicol

Constipation, Hypophosphatemia, Parenteral Nutrition, Total + 4 more
Treatment
1 FDA approval
20 Active Studies for Visicol

What is Visicol

Sodium phosphate, dibasicThe Generic name of this drug
Treatment SummarySodium phosphate is a type of medication that helps to stimulate a bowel movement by increasing fluid in the small intestine. It usually takes between 30 minutes and 6 hours for the laxative to work.
K Phos Neutralis the brand name
image of different drug pills on a surface
Visicol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
K Phos Neutral
Sodium phosphate, dibasic
1977
15

Approved as Treatment by the FDA

Sodium phosphate, dibasic, also known as K Phos Neutral, is approved by the FDA for 1 uses which include Parenteral Nutrition, Total .
Parenteral Nutrition, Total

Effectiveness

How Visicol Affects PatientsSodium phosphate makes stools softer and easier to pass through the large intestine.
How Visicol works in the bodySodium phosphate is believed to work by adding more substances to the intestines, which causes an imbalance of water in the intestine. This imbalance draws in more water, creating a gradient that helps speed up the intestines.

When to interrupt dosage

The prescribed dosage of Visicol is contingent upon the indicated condition, including fluid and electrolyte upkeep treatment, Fluid substitution therapy and Irrigation. The quantity of dosage is subject to the technique of administration (e.g. Liquid or Tablet, coated) laid out in the table below.
Condition
Dosage
Administration
Hypophosphatemia
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution
Parenteral Nutrition, Total
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution
Bowel preparation therapy
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution
Colonoscopy
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution
Surgical Procedures
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution
severe constipation
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution
Constipation
, 10.0 mL, 195.0 mg, 0.0875 mg/mL, 398.0 mg, 0.84 %, 852.0 mg, 142.0 mg/mL, 0.034 mL/mL, 0.187 mg/mL, 0.493 mg/mL, 350.0 mg/mL, 70.0 mg/mL, 0.042 %, 180.0 mg/mL, 900.0 mg/mL, 60.0 mg/mL, 4.3 mg/mL, 4.1 mg/mL, 0.01 mg/mg, 0.49 mg/mL, 0.42 mg/mL, 1.242 mg/mL, 0.12 mg/mL, 0.28 mg/mL, 3.05 mg/mL, 7.58 mg/mL, 268.0 mg/mL, 356.9575 mg/mL
, Spray, Intravenous, Kit, Kit - Intravenous, Oral, Tablet, effervescent, Tablet, effervescent - Oral, Liquid - Buccal, Spray - Buccal, Irrigation, Irrigant - Irrigation, Irrigant, Liquid, Buccal, Solution, Topical, Solution - Intravenous, Liquid - Topical, Liquid - Irrigation, Tablet, Tablet - Oral, Enema, Tablet, coated, Injection, solution - Intravenous, Injection, solution, Solution - Oral, Tablet, coated - Oral, Enema - Rectal, Solution - Respiratory (inhalation), Respiratory (inhalation), Liquid - Oral, Rectal, Injection, Injection - Intravenous, Solution - Irrigation, Powder, Powder - Oral, Intraocular, Kit; Solution, Powder, for solution - Intraocular, Kit; Solution - Intraocular; Irrigation, Intraocular; Irrigation, Kit; Solution - Intraocular, Powder, for solution

Warnings

Visicol has four contraindications and should not be used in coordination with the conditions given in the following table.There are 20 known major drug interactions with Visicol.
Common Visicol Drug Interactions
Drug Name
Risk Level
Description
Alloin
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin.
Calcium polycarbophil
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Calcium polycarbophil.
Chlorpropamide
Minor
Sodium phosphate, dibasic may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.
Frangula purshiana bark
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Frangula purshiana bark.
Konjac mannan
Minor
The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Konjac mannan.
Visicol Toxicity & Overdose RiskRats have a lethal dose of sodium phosphate of 250mg/kg when given intramuscularly and 8290mg/kg when given orally. High levels of phosphate in the body can cause tetany, dehydration, low blood pressure, rapid heartbeat, extreme fever, and even coma. Smaller patients are more at risk for experiencing phosphate toxicity.
image of a doctor in a lab doing drug, clinical research

Visicol Novel Uses: Which Conditions Have a Clinical Trial Featuring Visicol?

54 active clinical trials are ongoing to investigate the efficacy of Visicol in providing Electrolyte replacement, proctoscopy and Irrigation for treatment of certain conditions.
Condition
Clinical Trials
Trial Phases
severe constipation
0 Actively Recruiting
Bowel preparation therapy
1 Actively Recruiting
Phase 1, Phase 2
Colonoscopy
3 Actively Recruiting
Not Applicable
Constipation
18 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1
Surgical Procedures
0 Actively Recruiting
Hypophosphatemia
1 Actively Recruiting
Phase 2
Parenteral Nutrition, Total
0 Actively Recruiting

Visicol Reviews: What are patients saying about Visicol?

5Patient Review
1/2/2009
Visicol for Emptying of the Bowel
Easy to use, and the pills went down easily. I was worried about taking so many at once, but it wasn't a problem.
4Patient Review
11/30/2007
Visicol for Emptying of the Bowel
I experienced an irregular heartbeat and low potassium levels in my blood.
2Patient Review
3/20/2009
Visicol for Emptying of the Bowel
Unfortunately, this caused me a lot of pain and vomiting. I'm still dealing with the after-effects weeks later.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about visicol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Visicol used for?

"The VISICOL colonoscopy prep medication is only to be used by adults aged 18 and over. It works by causing diarrhea, which in turn cleans out the colon before the procedure. This is important because it allows your doctor to get a better view of the inside of the colon."

Answered by AI

Is Visicol still on the market?

"This product is no longer available under the Visicol name. If the FDA has approved generic versions of this product, there may be generic equivalents available."

Answered by AI

Clinical Trials for Visicol

Image of Center for Nutraceutical and Dietary Supplement Research in Memphis, United States.

Inno Cleanse for Abdominal Bloating

18+
All Sexes
Memphis, TN
The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanseâ„¢, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months. Despite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness. Therefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.
Recruiting
Paid Trial
Center for Nutraceutical and Dietary Supplement ResearchRichard Bloomer, PhD
Image of Banner - University Medical Center South in Tucson, United States.

Dexmedetomidine + Dexamethasone for Postoperative Pain

18 - 75
All Sexes
Tucson, AZ
The goal of this clinical study is to improve upon the standard practice of utilizing nerve blocks to enhance the satisfaction of patients undergoing shoulder, or foot and ankle surgery regarding their quality of pain control, the duration of their nerve blocks, as well as the avoidance of opioid medications and subsequently their undesirable side effects. The researchers hypothesize that dexmedetomidine and dexamethasone (Dex-Dex) will work synergistically as adjuncts in a low, non-weight based formula. This would allow the investigators to improve patient satisfaction by providing them with a superior means of pain control that is longer in duration with a decreased probability of unwanted side effects. The proposed clinical study will be a prospective, randomized control trial.
Phase 1 & 2
Waitlist Available
Banner - University Medical Center SouthRonald Tang, MD
Have you considered Visicol clinical trials? We made a collection of clinical trials featuring Visicol, we think they might fit your search criteria.Go to Trials
Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada
The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumediâ„¢ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).
Phase 2 & 3
Waitlist Available
Hamilton Health SciencesElyanne Ratcliffe, MD
Have you considered Visicol clinical trials? We made a collection of clinical trials featuring Visicol, we think they might fit your search criteria.Go to Trials
Image of University of Alberta in Edmonton, Canada.

Pelvic Health Rehabilitation for Breast and Gynecologic Cancer

18+
Female
Edmonton, Canada
The GYVE study aims at testing an online program (eModule) to help people who have had breast or gynecologic cancer and are experiencing pelvic health issues like urinary incontinence and pain during sex. These cancers and their treatments can cause significant pelvic health problems, affecting daily life and quality of life. Physiotherapy can help, but access is often limited due to costs and other barriers. The study will involve 20 participants from Quebec and Edmonton, who will take part in a 12-week program with weekly online group sessions led by a physiotherapist. Topics include pelvic floor muscle training, use of vaginal moisturizers, hydration, diet, and pain management. Led by experts in cancer rehabilitation and pelvic health, the study aims to provide valuable information on the feasibility and effectiveness of the eModule, potentially leading to broader implementation to help more people with lived experience of cancer.
Recruiting
Has No Placebo
University of Alberta (+1 Sites)
Image of Northwestern Memorial Hospital in Chicago, United States.

AI-Assisted Colonoscopy for Polyp Detection

18+
All Sexes
Chicago, IL
Based on prior studies, trainee and practicing gastroenterologists miss pre-cancerous polyps (adenomas and serrated polyps) during colonoscopy. The use of computer-aided detection (CADe) systems, a form of artificial intelligence (AI) has been shown to help identify colorectal lesions for practicing gastroenterologists. However, less is known how AI impacts polyp detection for trainees. The investigators are conducting a tandem colonoscopy study wherein a portion of the colon is examined first by the trainee and then the attending physician. For each procedure, randomization will occur which will determine whether or not the trainee will utilize AI for their examination of the colon. At the end of the study, the investigators will determine whether AI helps trainees miss fewer polyps during colonoscopy. The investigators will also conduct interviews with trainees to understand how AI impacts colonoscopy training.
Recruiting
Has No Placebo
Northwestern Memorial HospitalRajesh Keswani, MD
Have you considered Visicol clinical trials? We made a collection of clinical trials featuring Visicol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security